Verve Therapeutics (VERV) Short Interest Ratio & Short Volume $7.40 -0.08 (-1.07%) (As of 07/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Verve Therapeutics Short Interest DataCurrent Short Interest15,400,000 sharesPrevious Short Interest15,180,000 sharesChange Vs. Previous Month+1.45%Dollar Volume Sold Short$110.26 millionShort Interest Ratio11.2 Days to CoverLast Record DateJuly 15, 2024Outstanding Shares83,960,000 sharesFloat Size65,200,000 sharesShort Percent of Float23.62%Today's Trading Volume857,791 sharesAverage Trading Volume1,305,524 sharesToday's Volume Vs. Average66% Short Selling Verve Therapeutics ? Sign up to receive the latest short interest report for Verve Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVERV Short Interest Over TimeVERV Days to Cover Over TimeVERV Percentage of Float Shorted Over Time Ad Porter & CompanyNvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.To see Porter Stansberry's new AI prediction go here now. Verve Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202415,400,000 shares $110.26 million +1.5%23.6%11.2 $7.16 6/30/202415,180,000 shares $74.08 million -14.0%23.3%11.2 $4.88 6/15/202417,643,600 shares $95.63 million -5.7%27.6%12.2 $5.42 5/31/202418,710,000 shares $97.10 million +6.4%31.3%13.4 $5.19 5/15/202417,590,000 shares $109.59 million +6.4%29.4%12.4 $6.23 4/30/202416,540,000 shares $99.41 million +5.4%30.2%12.6 $6.01 Get the Latest News and Ratings for VERV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 4/15/202415,690,000 shares $114.69 million +2.2%28.6%12.3 $7.31 3/31/202415,360,000 shares $203.98 million +8.9%28.0%12.3 $13.28 3/15/202414,100,000 shares $194.72 million +12.6%25.7%12.8 $13.81 2/29/202412,520,000 shares $213.47 million -0.6%22.9%11 $17.05 2/15/202412,590,000 shares $167.20 million +1.8%23.0%10.7 $13.28 1/31/202412,370,000 shares $133.84 million +0.1%21.9%7.7 $10.82 1/15/202412,360,000 shares $157.84 million +5.4%21.9%7.2 $12.77 12/31/202311,730,000 shares $163.52 million +4.4%22.9%7 $13.94 12/15/202311,240,000 shares $155.79 million -21.8%21.9%6.7 $13.86 11/30/202314,380,000 shares $162.21 million +7.7%28.0%9.2 $11.28 11/15/202313,350,000 shares $153.39 million +5.2%30.8%9.5 $11.49 10/31/202312,690,000 shares $152.79 million +11.1%29.6%13.2 $12.04 10/15/202311,420,000 shares $133.61 million -6.2%26.7%16 $11.70 9/30/202312,180,000 shares $161.51 million +2.0%28.4%18.2 $13.26 9/15/202311,940,000 shares $151.40 million +0.2%27.9%19.4 $12.68 8/31/202311,920,000 shares $153.41 million +6.7%28.2%18.6 $12.87 8/15/202311,170,000 shares $176.49 million +4.5%26.4%17.9 $15.80 7/31/202310,690,000 shares $219.04 million -10.2%26.5%17.2 $20.49 7/15/202311,900,000 shares $237.29 million +0.5%29.5%19.2 $19.94 6/30/202311,840,000 shares $222 million +2.5%29.3%18.3 $18.75 6/15/202311,550,000 shares $229.15 million -6.6%28.6%16.6 $19.84 5/31/202312,360,000 shares $191.33 million -1.9%30.6%17.8 $15.48 5/15/202312,600,000 shares $222.52 million -4.0%31.2%16.7 $17.66 4/30/202313,120,000 shares $209.00 million -2.3%34.5%17.5 $15.93 4/15/202313,430,000 shares $202.12 million -0.5%35.3%17.9 $15.05 3/31/202313,500,000 shares $194.67 million -1.5%35.6%18.3 $14.42 3/15/202313,700,000 shares $233.59 million No Change36.1%19.3 $17.05 2/28/202313,700,000 shares $260.30 million +1.0%36.1%17 $19.00 2/15/202313,570,000 shares $294.74 million +5.9%35.9%17.6 $21.72 1/31/202312,820,000 shares $291.66 million +0.2%31.6%13.9 $22.75 1/15/202312,790,000 shares $293.40 million +2.6%31.5%13.3 $22.94 12/30/202212,470,000 shares $241.29 million +13.8%32.5%13 $19.35 12/15/202210,960,000 shares $213.94 million +8.4%29.0%11.1 $19.52 11/30/202210,110,000 shares $234.86 million +1.3%26.7%9.4 $23.23“Generational Bull Run” Incoming (Ad)LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. 11/15/20229,980,000 shares $260.08 million -0.7%26.4%9.9 $26.06 10/31/202210,050,000 shares $378.89 million -6.3%26.9%9.6 $37.70 10/15/202210,730,000 shares $327.91 million -11.5%29.7%11.1 $30.56 9/30/202212,130,000 shares $416.67 million +23.0%33.6%10 $34.35 9/15/20229,860,000 shares $409.09 million +2.0%27.3%8.2 $41.49 8/31/20229,670,000 shares $370.94 million +0.8%27.7%8.8 $38.36 8/15/20229,590,000 shares $363.08 million +7.4%27.4%9 $37.86 7/31/20228,930,000 shares $219.86 million -10.0%30.4%8.8 $24.62 7/15/20229,920,000 shares $235.20 million +5.6%33.8%10.3 $23.71 6/30/20229,390,000 shares $143.48 million -5.5%37.7%13.6 $15.28 6/15/20229,940,000 shares $122.16 million +3.4%40.0%14.5 $12.29 5/31/20229,610,000 shares $145.69 million +2.2%38.8%13.7 $15.16 5/15/20229,400,000 shares $129.06 million +4.4%37.9%13.3 $13.73 4/30/20229,000,000 shares $134.28 million +6.6%36.0%13.4 $14.92 4/15/20228,440,000 shares $171.59 million -3.3%33.8%12 $20.33 3/31/20228,730,000 shares $199.22 million +7.6%35.2%12.3 $22.82 3/15/20228,110,000 shares $170.31 million +5.5%32.6%11.6 $21.00 2/28/20227,690,000 shares $251.08 million +0.9%31.0%12.2 $32.65 2/15/20227,620,000 shares $243.61 million +10.6%30.7%12.2 $31.97 1/31/20226,890,000 shares $198.57 million +11.3%27.6%11.8 $28.82 1/15/20226,190,000 shares $202.97 million +0.8%22.7%12.2 $32.79 12/31/20216,140,000 shares $226.38 million +8.5%22.5%14.3 $36.87 12/15/20215,660,000 shares $194.93 million +21.5%20.8%13.4 $34.44 11/30/20214,660,000 shares $158.81 million +21.4%17.1%12 $34.08 11/15/20213,840,000 shares $176.64 million +15.7%14.1%10.6 $46.00 10/29/20213,320,000 shares $154.01 million +11.4%12.4%9.6 $46.39 10/15/20212,980,000 shares $130.91 million +34.2%11.1%8.3 $43.93 9/30/20212,220,000 shares $104.34 million +17.5%8.3%5.4 $47.00 9/15/20211,890,000 shares $121.94 million +1.6%7.0%4.1 $64.52 8/31/20211,860,000 shares $130.13 million +17.0%7.6%3.9 $69.96 8/13/20211,590,000 shares $95.40 million No Change6.5%3.1 $60.00 VERV Short Interest - Frequently Asked Questions What is Verve Therapeutics' current short interest? Short interest is the volume of Verve Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 15,400,000 shares of VERV short. 23.62% of Verve Therapeutics' shares are currently sold short. Learn More on Verve Therapeutics' current short interest. What is a good short interest ratio for Verve Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VERV shares currently have a short interest ratio of 11.0. Learn More on Verve Therapeutics's short interest ratio. Which institutional investors are shorting Verve Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Verve Therapeutics: Ikarian Capital LLC, and PEAK6 Investments LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Verve Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.62% of Verve Therapeutics' floating shares are currently sold short. Is Verve Therapeutics' short interest increasing or decreasing? Verve Therapeutics saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 15,400,000 shares, an increase of 1.4% from the previous total of 15,180,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Verve Therapeutics' float size? Verve Therapeutics currently has issued a total of 83,965,000 shares. Some of Verve Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Verve Therapeutics currently has a public float of 65,200,000 shares. How does Verve Therapeutics' short interest compare to its competitors? 23.62% of Verve Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Verve Therapeutics: PTC Therapeutics, Inc. (7.77%), Janux Therapeutics, Inc. (10.44%), Amneal Pharmaceuticals, Inc. (4.13%), Rocket Pharmaceuticals, Inc. (10.62%), Protagonist Therapeutics, Inc. (5.56%), Deciphera Pharmaceuticals, Inc. (5.71%), Maravai LifeSciences Holdings, Inc. (7.37%), Catalyst Pharmaceuticals, Inc. (5.26%), Arvinas, Inc. (15.55%), Edgewise Therapeutics, Inc. (14.47%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.13 billion), Royal Caribbean Cruises Ltd. ($2.77 billion), Moderna, Inc. ($2.76 billion), Coinbase Global, Inc. ($2.36 billion), Rivian Automotive, Inc. ($2.22 billion), Paychex, Inc. ($2.02 billion), Tractor Supply ($1.81 billion), Enphase Energy, Inc. ($1.65 billion), Chesapeake Energy Co. ($1.62 billion), and Lululemon Athletica Inc. ($1.58 billion). View all of the most shorted stocks. What does it mean to sell short Verve Therapeutics stock? Short selling VERV is an investing strategy that aims to generate trading profit from Verve Therapeutics as its price is falling. VERV shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Verve Therapeutics? A short squeeze for Verve Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VERV, which in turn drives the price of the stock up even further. How often is Verve Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VERV, twice per month. The most recent reporting period available is July, 15 2024. More Short Interest Resources from MarketBeat Related Companies: PTC Therapeutics Short Interest Data Janux Therapeutics Short Interest Data Amneal Pharmaceuticals Short Interest Data Rocket Pharmaceuticals Short Interest Data Protagonist Therapeutics Short Interest Data Deciphera Pharmaceuticals Short Interest Data Maravai LifeSciences Short Interest Data Catalyst Pharmaceuticals Short Interest Data Arvinas Short Interest Data Edgewise Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VERV) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.